Subxiphoid-subcostal thoracoscopic thymectomy for seropositive myasthenia offers equivalent remission rates and potentially faster recovery

Peng Cao, Shan Hu, Wensheng Qu, Kangle Kong, Peng Han, Jiaqi Yue, Yu Deng, Xiangning Fu, Fan Li, and Bo Zhao

Abstract

OBJECTIVES: To compare the perioperative and follow-up outcomes of patients with myasthenia gravis (MG) receiving subxiphoid-subcostal or unilateral thoracoscopic thymectomy and to identify the factors affecting MG prognosis.

METHODS: From January 2013 to December 2019, a total of 137 consecutive MG patients received subxiphoid-subcostal thoracoscopic thymectomy (STT, n = 65) or conventional unilateral thoracoscopic thymectomy (UTT, n = 72). The primary outcomes of this study were perioperative complications, duration and expenses of hospitalization, VAS score and complete stable remission (CSR).

RESULTS: The patients receiving STT had significantly shorter drainage duration and postoperative hospital stay and lower hospitalization expenses (P < 0.01). Pain scores on postoperative Days 1, 3, 7 and 14 were significantly lower in patients undergoing STT (P < 0.01). The average follow-up was 54.3 ± 24.18 months, with a CSR rate of 30.6% and an overall effective rate of 87.3%. Through uni- and multivariable
analyses, shorter symptom duration and Myasthenia Gravis Foundation of America (MGFA) class I were independent predictors for CSR in MG patients receiving thymectomy.

**CONCLUSIONS:** The present study not only showed that STT was a safe and feasible technique for MG, with a potentially faster postoperative recovery, lower hospitalization expenses, less postoperative pain and equivalent remission rate, but also revealed that shorter symptom duration and MGFA class I were favourable prognostic factors for CSR.

**Keywords:** Myasthenia gravis • Thymectomy • Subxiphoid-subcostal • Thoracoscopic surgery • Prognostic factor

**ABBREVIATIONS**

| Abbreviation | Definition |
|--------------|------------|
| CSR          | Complete stable remission |
| D            | Death      |
| E            | Exacerbation |
| HR           | Hazard ratio |
| I            | Improved   |
| MG           | Myasthenia gravis |
| MGFA         | Myasthenia Gravis Foundation of America |
| MM           | Minimal manifestation |
| PR           | Pharmacological remission |
| STT          | Subxiphoid-subcostal thoracoscopic thymectomy |
| U            | Unchanged  |
| UTT          | Unilateral thoracoscopic thymectomy |
| VATS         | Video-assisted thoracoscopic surgery |
| W            | Worse      |

**INTRODUCTION**

Myasthenia gravis (MG) is a long-lasting and rare autoimmune disease caused by neuromuscular junction dysfunction and characterized by weakness and abnormal muscle fatigue [1, 2]. The presence of thymic lesions in MG patients was previously described by Norris in 1936 [3]. According to a recent study, about 80% of MG patients had thymic lesions [4]. Since Blalock removed a thymic tumour in a 19-year-old MG patient and significantly relieved the symptoms in 1939 [5], thymectomy has been considered as an important component in the MG management. However, prognostic factors in MG patients undergoing thymectomy still remain uncertain.

Thymectomy with median sternotomy has been gradually replaced by minimally invasive surgery that has the benefits of less trauma, fewer complications and equivalent efficacy, including conventional video-assisted thoracoscopic surgery (VATS; unilateral or bilateral), robotic-assisted VATS and subxiphoid VATS [6–8]. The subxiphoid approach thymectomy was first reported by Kido in 1999 [9], and since then, subxiphoid thymectomy has been successfully applied in managing MG [8–10]. The subxiphoid approach is ideal and superior in terms of broader operative field, less intercostal neuralgia [10–12]. Hence, the aim of the present retrospective study was not only to evaluate perioperative outcomes of subxiphoid-subcostal thoracoscopic thymectomy (STT) versus unilateral thoracoscopic thymectomy (UTT) for MG but also to study the follow-up results and to identify the factors affecting MG prognosis.

**MATERIALS AND METHODS**

**Ethical statement**

This retrospective study was reviewed and approved by the Ethics Committee of Tongji hospital (Approval Number: TJ-C20190602). Written informed consent about operative techniques and data-use agreement was obtained from all patients.

**Patients**

This was a retrospective study reviewing a prospectively collected database of MG patients undergoing STT or UTT from January 2013 to December 2019 at our department. All relevant data were within the Myasthenia Gravis Foundation of America. After being informed of the advantages and disadvantages of the two surgical methods, the final choice depended on the patient. The inclusion criteria were as follows: (i) Preoperative diagnosis of MG based on clinical symptoms, Tensilon test, electrophysiological test and serological test: detection of anti-acetylcholine-receptor antibodies; (ii) Diagnosis of thymic tumour by using chest computed tomography. And the exclusion criteria were: (i) Anterior mediastinal lesions larger than 6 cm that had invaded surrounding organs or neoadjuvant therapy had been given; (ii) Previous history of thoracic surgery, tuberculosis, preoperative pulmonary infection, diffuse emphysema; (iii) Coagulation dysfunction; (iv) Deformity of chest wall or spine; (v) American Society of Anesthesiologists (ASA) grade above III; (vi) Overweight (body mass index >30 kg/m²).

The clinical classification of MG was according to MGFA. The Quantitative Myasthenia Gravis (QMG) score was used to evaluate the severity of MG. Any patients with preoperative generalized symptoms, respiratory difficulties or bulbar symptoms were considered for pharmaceutical treatment, including pyridostigmine, prednisone or even plasmapheresis or intravenous immunoglobulins. All patients were discussed in a multidisciplinary board with neuroscientists with the aim to identify the surgical indication and to determine the appropriate timing of surgery based on the stability of MG symptoms. Thymectomy was merely performed when MG symptoms were significantly improved and daily dosage of prednisone was <20 mg/day, to reduce the risk of postoperative myasthenic crisis.

**Surgical procedures**

Following the induction of general anaesthesia and mechanical ventilation with single-lumen endotracheal intubation, the patient was placed in a supine position with the legs spread, and a
cushion was placed beneath the thoracic spine to elevate the chest (Fig. 1). The procedure of STT was similar to that reported previously [6]. During operation, the operator stood between the patients’ legs, while the assistant was on the right side of the patient to operate the camera (Fig. 1). A vertical skin incision of ∼3.0 cm was made first to expose the xiphoid and to serve as an observation port. The retrosternal space was created and enlarged by blunt separation with fingers. Under the guidance of the finger, two 0.5-cm extrapleural thoracic ports were created under the bilateral costal arches at the midclavicular lines to act as operating ports (Fig. 1). Thereafter, a 10-mm, 30-degree thoracoscope was introduced into the retrosternal space through the subxiphoid incision. Artificial pneumothorax was created with insufflation of carbon dioxide (CO₂) under a positive pressure of 8-cm H₂O which could shift the lung and diaphragm away to ensure a sufficient surgical field. The ultrasonic scalpel device was used for detachment, excision and coagulation. The bilateral mediastinal pleurae were incised first to expose the bilateral thoracic

Figure 1: (A) Placement of the monitor, patient, operator, assistant and nurse in subxiphoid-subcostal thoracoscopic thymectomy; (B) Surgical incision in subxiphoid-subcostal thoracoscopic thymectomy: (1) Subxiphoid incision for camera and CO₂; (2) Ultrasound scalpel; and (3) Grasping forceps.

Figure 2: Intraoperative view under subxiphoid-subcostal thoracoscopic thymectomy. (A) Retrosternal space and bilateral mediastinal pleurae; (B) left mediastinal pleura; (C) right phrenic nerve; and (D) view of the cervical region.
cavities. Then, the pericardial adipose tissue of bilateral diaphragmatic angle was dissected and bilateral phrenic nerves were identified. Along the anterior of bilateral phrenic nerves to the neck, the lateral edges of thymus and its surrounding adipose tissue were excised. The posterior edge of the thymus was separated from the pericardium to identify the innominate vein, and the junction of innominate vein and superior vena cava could be clearly exposed. After ligating the thymic veins, the thymus was stripped from the innominate vein. By grasping the thymus, the bilateral superior poles of thymus were easily dissected. The thymus in neck region was excised from the thyroid gland, innominate veins, brachiocephalic artery, aortopulmonary window and trachea (Fig. 2). The specimens were placed en-bloc in plastic bags and removed via the subxiphoid port. Haemostasis was assured and two 20-Fr drainage tubes were inserted into thoracic cavity via bilateral subcostal incisions.

The procedure of UTT was similar to that reported previously [13]. Following the induction of general anaesthesia, a traditional double-lumen endotracheal intubation was used for UTT. The operation was performed with the patient in lateral decubitus position. The right-sided approach was used unless the tumour was predominantly located on the left. A 3-cm operation and camera ports were placed in the performed in the fifth and seventh intercostal space and at the anterior and mid-axillary line, respectively. Thymectomy was started from the phrenic nerve and diaphragm and proceeded gradually to the thoracic inlet. Then the innominate vein was identified and thymic veins were exposed and ligated using an ultrasonic scalpel. The dissection was continued up to the vicinity of contralateral phrenic nerve. The superior pole of thymus and fat tissues in neck region was dissected. Once the thymus and surrounding fat tissues were dissected free, it was placed into a plastic bag and removed through the incision. Two chest tubes were inserted and incisions were sutured.

Follow-up

All patients were regularly followed up, and the clinical data were obtained by reviewing the electronic medical records, nursing records, outpatient services or by direct telephone interview. The frequency of follow-up was once in the first month after surgery, once in the fourth month after surgery and then every 6 months in the following years. The drug management of MG patients was based on the patient’s symptoms and conducted under the guidance of experienced neurologists. Therapeutic responses were assessed according to the MGFA Post-Intervention Status [14]. The criteria defining the MGFA Post-Intervention Status required that the patient be examined by a skilled neurologist. An effective status in this study included complete stable remission (CSR), pharmacological remission (PR), minimal manifestation (MM), and improved (I), while an ineffective status included unchanged (U), worse (W), exacerbation (E) or death (D).

Statistical analysis

All statistical analyses were performed using IBM SPSS Statistics for Windows, Version 22.0 (Armonk, NY: IBM Corp.). Continuous variables were presented as mean ± standard deviation, and a Student’s t-test was used to compare the means if the data were normally distributed; otherwise, the variables were displayed as median and range, and non-parametric Kruskal–Wallis test should
Table 1: Comparison of clinical and pathological data between two groups

| Characteristics                              | STT (n = 65) | UTT (n = 72) | P-value |
|---------------------------------------------|--------------|--------------|---------|
| Age (years), median (range)                 | 49 (18–67)   | 52 (18–71)   | 0.581   |
| Sex, n (%)                                  |              |              | 0.667   |
| Male                                        | 34 (52.3)    | 35 (48.6)    |         |
| Female                                      | 34 (52.3)    | 35 (48.6)    |         |
| BMI (kg/m²), median (range)                 | 22.3 (16.1–29.8) | 22.7 (15.9–30.0) | 0.473   |
| Smokers, n (%)                              | 13 (22.3)    | 16 (21.6)    | 0.851   |
| Comorbidity, n (%)                          |              |              | 0.958   |
| Extrathoracic malignancy                    | 1 (1.5)      | 2 (2.8)      |         |
| Chronic obstructive pulmonary disease       | 9 (13.8)     | 11 (15.2)    |         |
| Hypertension                                | 7 (10.8)     | 8 (11.1)     |         |
| Diabetes mellitus                           | 3 (4.6)      | 5 (6.9)      |         |
| Cardiac diseases                            | 4 (6.2)      | 4 (5.6)      |         |
| Others                                      | 1 (1.5)      | 2 (2.8)      |         |
| None                                        | 40 (61.6)    | 40 (55.6)    |         |
| ASA classification, median (range)          | 1 (1–3)      | 1 (1–3)      | >0.999  |
| WHO histologic type of thymomas, n (%)      |              |              | 0.960   |
| Thymoma                                     | 19 (29.2)    | 22 (30.6)    |         |
| Thymic hyperplasia                          | 27 (41.6)    | 32 (44.4)    |         |
| Thymic cyst                                 | 18 (27.7)    | 16 (22.2)    |         |
| Thymus atrophy                              | 1 (1.5)      | 2 (2.8)      |         |
| WHO histologic type of thymomas             |              |              | 0.960   |
| A/AB                                        | 8 (12.3)     | 10 (13.9)    |         |
| B1/B2/B3                                    | 10 (15.4)    | 12 (16.7)    |         |
| C                                           | 1 (1.5)      | 0 (0.0)      |         |
| Masaoka–Koga stage, n (%)                   | 15 (23.0)    | 18 (25.0)    | 0.291   |

ASA: American Society of Anesthesiologists; BMl: body mass index; MGFA: Myasthenia Gravis Foundation of America; QMG: Quantitative Myasthenia Gravis; WHO: World Health Organization.

be used. Categorical variables were presented as count and percentages, and were compared using chi-square test (or Fisher’s exact test) as appropriate. Survival curves were plotted for the patients using the Kaplan–Meier method and analysed using the log-rank test. Uni- and multivariable analyses were performed by Cox regression analysis to confirm the prognostic factors of CSR. Factors with a P-value of <0.2 were included for multivariable analysis to assess the independent prognostic factors affecting CSR. A P-value of <0.05 was considered statistically significant.

RESULTS

Baseline characteristics and perioperative results

A total of 137 patients between January 2013 and December 2019 were included in this analysis, of which 47.4% of patients received STT. Demographics for the two groups were shown in Table 1. There were no statistically significant differences between the two groups, including age, sex, body mass index, smoking, comorbidity, ASA score and MGFA clinical classification, maximal tumour size, World Health Organization (WHO) histologic type and pathological Masaoka–Koga stage of thymomas. However, there was a patient with type-C thymoma in STT group, but not in UTT group.

All perioperative outcomes between STT and UTT groups were shown in Table 2. No statistically significant differences were found in operation time, intraoperative lowest pulse oxygen saturation, blood loss and perioperative complications between both groups. However, in UTT group, there was one patient with contralateral phrenic nerve paralysis postoperatively, but none in STT group. Two cases (2/72) in UTT group and 1 (1/65) in STT group were converted to thoracotomy due to chest adhesions or bleeding. The incidence of postoperative crisis and re-tracheal intubation was low in both groups. In addition, there was no 30-day mortality in both groups. But compared with the patients undergoing UTT, the patients receiving STT had significantly shorter drainage duration, postoperative hospital stay, and lower hospitalization expenses (P = 0.006, P = 0.002, P = 0.004, respectively). VAS scores on postoperative Days 1, 3, 7 and 14 were significantly higher in patients undergoing UTT (P = 0.002, P = 0.003, P = 0.005, P = 0.007, respectively), but there was no significant difference on
DISCUSSION

In this study, we evaluated the perioperative and follow-up results of patients receiving STT and UTT and found that STT was a safe and feasible technique for MG, with a faster recovery, lower hospitalization expenses, less postoperative pain and equivalent remission rate. The results also suggested that MG patients with shorter symptom duration and MGFA class I benefitted more from the surgery.

Over the past several decades, multiple surgical techniques have been described for thymectomy in treating MG and thymic tumours, including trans-sternal thymectomy and now popular minimally invasive surgery, as long as all thymus and surrounding fat were removed [2, 14]. With advances of surgical instruments and techniques, VATS thymectomy has become a popular alternative to trans-sternal thymectomy in recent years [15]. At present, the lateral approach is the main choice in various approaches of VATS thymectomy. However, the lateral approach has its limitations, including difficulty in identifying the contralateral phrenic nerve, narrow operative field in neck region, inadequate removal of fat on the contralateral side and intercostal nerve paralysis or neuralgia [16]. Although the bilateral approach could provide a wide surgical field and expose bilateral phrenic nerves, it leads to more incisions and traumas. Although there were efforts to reach a consensus regarding the standard VATS thymectomy, no consensus has been available so far [17], and the choice of surgical approach is usually based on the experience and preference of the surgeon.

Hsu [6] and Suda et al. [12, 16] previously reported that subxiphoid VATS thymectomy without intercostal incisions had several advantages. First, the excellent operative field offered by a subxiphoid approach could easily help to confirm the location of the superior poles of thymus and bilateral phrenic nerves. The broad visualization allowed the maximum resection of thymus and its surrounding adipose tissues and reduced the chance of accidental vessel laceration or phrenic nerve injury. Secondly, double-lumen intubation and single-lung ventilation were necessary for UTT, which met the needs of intraoperative lung ventilation and

**Table 3:** The MGFA-PIS of patients after thymectomy

| MGFA-PIS      | Overall (n = 134) | STT (n = 64) | UTT (n = 70) | P-value |
|---------------|------------------|-------------|-------------|---------|
| Effective, n (%) | 117 (87.3) | 55 (85.9) | 62 (88.6) | 0.985 |
| CSR            | 41 (30.6) | 20 (31.2) | 21 (30.0) |          |
| PR             | 32 (23.9) | 15 (23.4) | 17 (24.3) |          |
| MM             | 30 (22.4) | 14 (21.9) | 16 (22.9) |          |
| I              | 14 (10.4) | 6 (9.4) | 8 (11.4) |          |
| Ineffective, n (%) | 17 (12.7) | 9 (14.1) | 8 (11.4) | 0.997 |
| U              | 9 (6.7) | 5 (7.8) | 4 (5.7) |          |
| W              | 4 (3.0) | 2 (3.1) | 2 (2.9) |          |
| E              | 2 (1.5) | 1 (1.6) | 1 (1.4) |          |
| D              | 2 (1.5) | 1 (1.6) | 1 (1.4) |          |

Effective: CSR + PR + MM + I; Ineffective: U + W + E + D.

**Table 4:** Univariable analysis for predictors of CSR after thymectomy

| Variables            | Total (n = 134) | CSR (n = 41) | HR (95% CI) | P-value |
|----------------------|-----------------|-------------|-------------|---------|
| Sex                  |                 |             |             |         |
| Male                 | 65              | 20 (30.8%)  | 1.075 (0.581–1.673) | 0.839 |
| Female               | 69              | 21 (30.4%)  | 1           |         |
| Onset age            |                 |             |             |         |
| <40 years            | 75              | 26 (34.7%)  | 2.073 (1.084–3.965) | 0.048* |
| >40 years            | 59              | 15 (25.4%)  | 1           |         |
| Symptom duration     |                 |             |             |         |
| <1 year              | 81              | 30 (37.0%)  | 4.106 (1.628–9.750) | 0.005* |
| >1 year              | 53              | 11 (20.2%)  | 1           |         |
| MGFA clinical        |                 |             |             |         |
| classification       |                 |             |             |         |
| I                    | 63              | 24 (38.1%)  | 3.024 (1.260–6.729) | 0.029* |
| II and above         | 71              | 17 (24.0%)  | 1           |         |
| Pathology            |                 |             |             |         |
| Non-thymoma          | 93              | 30 (32.3%)  | 1.472 (0.906–2.381) | 0.382 |
| Thymoma              | 41              | 11 (26.7%)  | 1           |         |
| Surgical approach    |                 |             |             |         |
| STT                  | 64              | 20 (31.3%)  | 1.193 (0.703–2.065) | 0.947 |
| UTT                  | 70              | 21 (30.0%)  | 1           |         |

CI: confidence interval; CSR: complete stable remission; HR: hazard ratio; MGFA: Myasthenia Gravis Foundation of America; STT: subxiphoid-subcostal thorascoscopic thymectomy; UTT: unilateral thorascoscopic thymectomy.

Neurological outcome

At the time of completion of data gathering for analysis, 3 (4.2%) patients were lost to follow-up evaluation, including 1 in STT group and 2 in UTT group. The remaining 134 patients had a median follow-up period of 52 months (range: 12–96 months; mean: 54.3 ± 24.18 months). Of the 134 patients, a total of 30.6% patients achieved CSR, 23.6% patients achieved PR, 22.4% patients had MM, 14.4% patients improved, 6.7% patients were unchanged, 3.0% patients were worse, in 2 patients (1.5%) there was exacerbation and 2 patients (1.5%) died of respiratory failure caused by myasthenia crisis during the follow-up period (1 in STT group and 1 in UTT group) (Table 3). Overall, treatment was effective in 87.3% (117/134) patients (CSR + PR + MM + I) and ineffective in 12.7% (17/134) patients (U + W + E + D). There were no significant differences in CSR, effective status and cumulative probability of CSR between STT and UTT (P = 0.985, P = 0.917, respectively) (Table 3 and Fig. 3B).

Possible prognostic factors of CSR for MG patients after thymectomy were evaluated (Tables 4 and 5). Univariable analysis (n = 134) showed that onset age (<40 years vs ≥40 years, hazard ratio (HR) = 2.073, P = 0.048), symptom duration (<1 year vs ≥1 year, HR = 4.106, P = 0.005) and MGFA clinical classification (I versus II and above, HR = 3.154, P = 0.029) were predictors of response to thymectomy in MG patients, whereas sex, pathology and surgical approach were not significantly correlated with neurological outcome. In the multivariable analysis, shorter symptom duration (<1 year: HR = 3.908, P = 0.019) and MGFA class I (HR = 3.271, P = 0.035) were considered as independent favourable predictors for a higher CSR in MG patients receiving thymectomy, while the onset age was not considered as a significant prognostic factor (<40 years: HR = 1.973, P = 0.061).
our present research also revealed that pain 
erative pain of STT was significantly lower than that of lateral 
tion for STT. Third, previous studies had shown that the postop-
cause of impaired lung function or double-lumen endotracheal 
tubation. Although there was no statistical difference in the 
lowest intraoperative pulse oxygen saturation between the two 
groups in our study [96.6 ± 6.37 vs 95.2 ± 7.61, (%)], we believed 
that for patients who cannot tolerate single-lung ventilation be-
successful performed under a single-lumen 

Table 5: Multivariable analysis for predictors of CSR after thymectomy

| Variables                        | SE  | Wald | HR   | 95% CI           | P-value |
|----------------------------------|-----|------|------|------------------|---------|
| Onset age                        |     |      |      |                  |         |
| <40 years vs >40 years           | 0.595 | 3.663 | 1.973 | 0.927–3.989      | 0.061   |
| Symptom duration                 | 0.651 | 12.719 | 3.908 | 1.583–9.6813     | 0.019*  |
| MGFA clinical classification     |     |      |      |                  |         |
| I versus II and above            | 0.637 | 11.206 | 3.271 | 1.295–6.840      | 0.035*  |

CI: confidence interval; CSR: complete stable remission; HR: hazard ratio; SE: standard error.

adequate surgical field [7, 8, 10–12]. However, as shown in our 
study, STT could be successfully performed under a single-lumen intubation. Although there was no statistical difference in the 
lowest intraoperative pulse oxygen saturation between the two 
groups in our study [96.6 ± 6.37 vs 95.2 ± 7.61, (%)], we believed 
that for patients who cannot tolerate single-lumen ventilation be-
taneous intervention. As reported in the previous literature, our 
follow-up study, the prognosis of MG patients with thymoma was equivalent to that of patients without thymoma. As reported in the previous literature, our results also showed that thymectomy could 

The single-centre retrospective nature of the study represents 
its major obvious limitation. All patients were selected from 
only one clinical centre, and thus, intrinsic bias may exist, in- 
cluding the surgeons’ preferences. In addition, we did not per-
form propensity score matching analysis because of the small 
sample size. Therefore, further studies with larger samples mul-
ticentre prospective randomized controlled trials should be 

| Variables                        | SE  | Wald | HR   | 95% CI           | P-value |
|----------------------------------|-----|------|------|------------------|---------|
| Onset age                        |     |      |      |                  |         |
| <40 years vs >40 years           | 0.595 | 3.663 | 1.973 | 0.927–3.989      | 0.061   |
| Symptom duration                 | 0.651 | 12.719 | 3.908 | 1.583–9.6813     | 0.019*  |
| MGFA clinical classification     |     |      |      |                  |         |
| I versus II and above            | 0.637 | 11.206 | 3.271 | 1.295–6.840      | 0.035*  |

CI: confidence interval; CSR: complete stable remission; HR: hazard ratio; SE: standard error.

adequate surgical field [7, 8, 10–12]. However, as shown in our 
study, STT could be successfully performed under a single-lumen intubation. Although there was no statistical difference in the 
lowest intraoperative pulse oxygen saturation between the two 
groups in our study [96.6 ± 6.37 vs 95.2 ± 7.61, (%)], we believed 
that for patients who cannot tolerate single-lumen ventilation be-
taneous intervention. As reported in the previous literature, our 
follow-up study, the prognosis of MG patients with thymoma was equivalent to that of patients without thymoma. As reported in the previous literature, our results also showed that thymectomy could 

The single-centre retrospective nature of the study represents 
its major obvious limitation. All patients were selected from 
only one clinical centre, and thus, intrinsic bias may exist, in- 
cluding the surgeons’ preferences. In addition, we did not per-
form propensity score matching analysis because of the small 
sample size. Therefore, further studies with larger samples mul-
ticentre prospective randomized controlled trials should be 

CONCLUSION

In conclusion, the present study showed that STT is a safe and 
effective technique for the management of MG patients, with a 
shorter drainage duration and postoperative hospital stay, lower hospitalization expenses, less postoperative pain and 
equivalent CSR rate. Although our research was limited by be-
ing a retrospective study, it still revealed that shorter symptom 
duration and MGFA class I were favourable prognostic factors 
for CSR.

Conflict of interest: none declared.

Author contributions

Peng Cao: Data curation; Methodology; Software; Writing—original draft.
Shan Hu: Data curation. Wensheng Qu: Conceptualization; Data curation.
Kangle Kong: Formal analysis. Peng Han: Data curation. Jiaqi Yue: Software.
Yu Deng: Conceptualization. Xiangning Fu: Project administration. Fan Li: 
Conceptualization; Validation; Writing—review & editing. Bo Zhao: 
Conceptualization; Resources; Supervision, Writing—review & editing.

Reviewer information

Interactive CardioVascular and Thoracic Surgery thanks Tibor Krajc, William 
Grossi, Rui Haddad and the other anonymous reviewers for their contribution 
to the peer review process of this article.
REFERENCES

[1] Gilhus NE, Venshuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015;14:1023–36.
[2] Gilhus NE. Myasthenia gravis. N Engl J Med 2016;375:2570–81.
[3] Norris EH. The thymoma and thymic hyperplasia in myasthenia gravis with observations on the general pathology. Am J Cancer 1936;27:421-e33.
[4] Huang X, Liu WB, Men LN, Feng HY, Li Y, Luo CM et al. Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurol Sci 2013;34:911–17.
[5] Blalock A, Mason MF, Morgan HJ, Riven SS. Myasthenia gravis and tumors of the thymic region: report of a case in which the tumor was removed. Ann Surg 1939;110:544–61.
[6] Hsu CP, Chuang CY, Hsu NY, Chen CY. Comparison between the right side and subxiphoid bilateral approaches in performing video-assisted thoracoscopic extended thymectomy for myasthenia gravis. Surg Endosc 2004;18:821–4.
[7] Pennathur A, Qureshi I, Schuchert MJ, Dhupar R, Ferson PF, Gooding WE et al. Comparison of surgical techniques for early-stage thymoma: feasibility of minimally invasive thymectomy and comparison with open resection. J Thorac Cardiovasc Surg 2011;141:694–701.
[8] Li J, Qi G, Liu Y, Zheng X, Zhang X. Meta-analysis of subxiphoid approach versus lateral approach for thoracoscopic thymectomy. J Cardiothorac Surg 2020;15:89.
[9] Kido T, Hazama K, Inoue Y, Tanaka Y, Takao T. Resection of anterior mediastinal masses through an infrasternal approach. Ann Thorac Surg 1999;67:263–5.
[10] Xu H, Liu D, Li Y, Yang L, Wang F, Wang W et al. The outcomes of subxiphoid thoracoscopic versus video-assisted thoracic surgery for thymic diseases. J Laparoendosc Adv Surg Tech A 2020;30:508–13.
[11] Yano M, Moriyama S, Haneda H, Okuda K, Kawano O, Oda R et al. The subxiphoid approach leads to less invasive thoracoscopic thymectomy than the lateral approach. World J Surg 2017;41:763–70.
[12] Suda T, Tochii D, Tochii S, Takagi Y. Trans-subxiphoid robotic thymectomy. Interact CardioVasc Thorac Surg 2015;20:669–71.
[13] Li Q, Sihoe A, Wang H, Gonzalez-Rivas D, Zhu Y, Xie D et al. Short-term outcomes of single- versus multi-port video-assisted thoracic surgery in mediastinal diseases. Eur J Cardiothorac Surg 2018;53:216–20.
[14] Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16–23.
[15] Mineo TC, Ambrogi V. Surgical techniques for myasthenia gravis: video-assisted thoracic surgery. Thorac Surg Clin 2019;29:165–75.
[16] Suda T, Hachimaru A, Tochii D, Maeda R, Tochii S, Takagi Y. Video-assisted thoracoscopic thymectomy versus subxiphoid single-port thymectomy: initial results. Eur J Cardiothorac Surg 2016;49(Suppl 1):i54–8.
[17] Zielinski M. Definitions and standard indications of minimally-invasive techniques in thymic surgery. J Vis Surg 2017;3:99.
[18] Wolfe GI, Kaminski HJ, Alban IB, Minisman G, Kuo HC, Marx A et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 2016;375:511–22.
[19] Qiu Z, Chen L, Lin Q, Wu H, Sun H, Zhou X et al. Perioperative outcomes and mid-term effects in performing video-assisted thoracoscopic extended thymectomy for myasthenia gravis: subxiphoid versus right thoracic approaches. J Thorac Dis 2020;12:1529–39.
[20] Budde JM, Morris CD, Gal AA, Mansour KA, Miller JL Jr. Predictors of outcome in thymectomy for myasthenia gravis. Ann Thorac Surg 2001;72:197–202.
[21] Tian W, Li X, Tong H, Weng W, Yang F, Jiang G et al. Surgical effect and prognostic factors of myasthenia gravis with thymomas. Throrac Cancer 2020;11:1288–96.
[22] Bachmann K, Burkhardt D, Schreiter I, Kafi J, Busch C, Thayssen G et al. Long-term outcome and quality of life after open and thoracoscopic thymectomy for myasthenia gravis: analysis of 131 patients. Surg Endosc 2008;22:2470–7.
[23] Yu S, Li F, Chen B, Lin J, Yang M, Fu X et al. Eight-year follow-up of patients with myasthenia gravis after thymectomy. Acta Neurol Scand 2015;131:94–101.
[24] Lin MW, Chang YL, Huang PM, Lee YC. Thymectomy for non-thymomatous myasthenia gravis: a comparison of surgical methods and analysis of prognostic factors. Eur J Cardiothorac Surg 2010;37:7–12.
[25] Masaoka A, Yamakawa Y, Niwa H, Fukai I, Kondo S, Kobayashi M et al. Extended thymectomy for myasthenia gravis patients: a 20-year review. Ann Thorac Surg 1996;62:853–9.
[26] Pompeo E, Taconi F, Massa R, Mineo D, Nahmias S, Mineo TC. Long-term outcome of thoracoscopic extended thymectomy for nonthymomatous myasthenia gravis. Eur J Cardiothorac Surg 2009;36:164–9.
[27] Mineo TC, Pompeo E, Lerut TE, Bernardi G, Coosemans W, Nofrioni I. Thoracoscopic thymectomy in autoimmune myasthenia: results of left-sided approach. Ann Thorac Surg 2000;69:1537–41.
[28] de Perrot M, Liu J, Bril V, McRae K, Bejjak A, Keshavjee SH. Prognostic significance of thymomas in patients with myasthenia gravis. Ann Thorac Surg 2002;74:1658–62.